Blood disorders known as myelodysplastic syndromes/neoplasms are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other potentially harmful consequences. A new study highlights the vital need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of blood cancers.
Tag: MDs
Magrolimab Plus Azacitidine Results in Promising Activity in Higher-Risk MDS Patients
In a new article published today in the Journal of Clinical Oncology, Moffitt Cancer Center physician-scientists, in collaboration with institutions from across the United States and the United Kingdom, share promising phase 1b trial results of a new combination therapy — magrolimab + azacitidine — for patients with higher-risk MDS.
Investigational Combo Therapy Shows Benefit for TP53 Mutant MDS and Acute Myeloid Leukemia Patients
Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology.
Signal Switch Gives MDS Cells a Competitive Advantage that Supports Disease Progression
A study published online April 20, 2020, in Nature Immunology, led by researchers at Cincinnati Children’s reports a possible new approach for treating myelodysplastic syndrome (MDS), which often can lead to leukemia.
Yale Cancer Center Announces Hematology Leadership Appointments
Yale Cancer Center announces the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program.